Skip to main content
Clinical Trials/NCT00296686
NCT00296686
Terminated
Phase 4

A Pilot Study of Treatment for Refractory Depression With Sequential Trials of Tranylcypromine, Tranylcypromine Plus Dextroamphetamine, Tranylcypromine Plus Triiodothyronine.

New York State Psychiatric Institute1 site in 1 country31 target enrollmentSeptember 2001

Overview

Phase
Phase 4
Intervention
Tranylcypromine
Conditions
Major Depression
Sponsor
New York State Psychiatric Institute
Enrollment
31
Locations
1
Primary Endpoint
Hamilton Depression Scale (HAM-D)
Status
Terminated
Last Updated
14 years ago

Overview

Brief Summary

This pilot study will assess the efficacy of several sequential pharmacological treatments for patients with Refractory Depression.

Detailed Description

This pilot study will recruit 40 patients with Major Depression and a history of at least two failed prior adequate somatic treatments. In addition to usual physical work-up, all patients will have extensive thyroid testing, and then will receive standard dose Tranylcypromine (i.e., max. 60 mg/d). Non-remitters will have dose increased to max. 120 mg/d if tolerated. Non-remitters to high dose Tranylcypromine will then have Dextroamphetamine added with frequent blood pressure monitoring to max. 40 mg/d. Non-remitters will have Triiodothyronine added to the Tranylcypromine.

Registry
clinicaltrials.gov
Start Date
September 2001
End Date
August 2006
Last Updated
14 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Ages between 18-65
  • Major Depression
  • At least two prior ineffective antidepressant trials (at least 2 different mechanisms) or 1 inadequate ECT trial (at least 8 bilateral treatments)
  • Physically healthy

Exclusion Criteria

  • Known Tranylcypromine allergy
  • Unable to follow tyramine-free diet
  • Known allergy, intolerance or prior addiction to any stimulant would preclude patient's inclusion in the Dextroamphetamine portion of the protocol
  • Current substance use disorder including alcohol)(past six months); ever dependent on stimulants would preclude Dextroamphetamine portion of the protocol
  • Unable or unwilling to discontinue antidepressants including OTC antidepressants such as St. John's Wort
  • History of psychosis, such as schizophrenia or psychotic depression; history of bipolar mania will be allowed if on adequate mood stabilizer
  • Suicidal ideation/activity that makes outpatient treatment unsafe, unless protocol can be conducted as inpatient
  • Current systolic BP \> 149 or diastolic BP \> 89 mm Hg (two readings); adequately treated hypertension is acceptable
  • Evidence of hypo- or hyperthyroidism
  • Pregnancy, lactation, refusal to use adequate birth control

Arms & Interventions

tranylcypromine

sequential tranylcypromine (TC) followed by TC + dextroamphetamine followed by TC + T3

Intervention: Tranylcypromine

tranylcypromine

sequential tranylcypromine (TC) followed by TC + dextroamphetamine followed by TC + T3

Intervention: Dextroamphetamine

tranylcypromine

sequential tranylcypromine (TC) followed by TC + dextroamphetamine followed by TC + T3

Intervention: Triiodothyronine

Outcomes

Primary Outcomes

Hamilton Depression Scale (HAM-D)

Time Frame: up to 10 mos.

Secondary Outcomes

  • Beck Depression Inventory (BDI)(up to 10 mos.)
  • Clinical Global Impression (CGI)(up to 10 mos.)
  • Patient Global Impression (PGI)(up to 10 mos.)

Study Sites (1)

Loading locations...

Similar Trials